CLEVER-1+ tumor-associated macrophages in gastric cancer immunotherapy resistance: integrating metabolic reprogramming and immunosuppression. (PubMed, Front Immunol) - Oct 8, 2026 - "The arrival of ICIs, especially anti-PD-1 antibodies such as nivolumab, has offered new treatment options...However, longer-term follow-up analyses have made it clear that a substantial proportion of patients either do not respond initially or relapse after an initial response. Thus, there is an urgent need to understand the mechanisms behind immunotherapy resistance."
Journal • Review • Esophageal Adenocarcinoma • Esophageal Cancer • Gastric Cancer • Oncology • Solid Tumor
|
|
Hao Yuan; Huaijue Qiu; Lin Wang; Nan Li; Yachao Li
|